



# Corporate Presentation

May 2024

**ROOTED IN  
INNOVATION**

# Forward Looking Statements and Important Notes

This presentation by VYNE Therapeutics Inc. ("VYNE") includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE's development plans and timelines for VYN201 and VYN202, VYNE's InhiBET™ platform, VYNE's cash runway through the end of 2025 and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this presentation which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE's ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE's ability to enroll patients and successfully progress, complete, and receive favorable results from, clinical trials of its product candidates; VYNE's ability to comply with various regulations applicable to its business; VYNE's ability to create intellectual property and the scope of protection it is able to establish and maintain for intellectual property rights covering its product candidates, including the projected terms of patent protection; risks that any of VYNE's patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE's patent applications may not be granted and potential competitors may also seek to design around VYNE's granted patents or patent applications; estimates of VYNE's expenses and capital requirements, and its ability to obtain additional capital on acceptable terms or at all; VYNE's expectations regarding licensing, business transactions and strategic operations; VYNE's future financial performance and liquidity; and volatility in VYNE's stock price may result in rapid and substantial increases or decreases in the stock price that may or may not be related to VYNE's operating performance or prospects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE's actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in VYNE's Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in VYNE's subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this presentation and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.





Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and VYNE's own internal estimates and research. While VYNE believes these third-party sources to be reliable as of the date of this presentation, VYNE has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while VYNE believes its own internal research is reliable, such research has not been verified by any independent source. You are cautioned not to give undue weight to any such information, projections and estimates.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. This presentation concerns product candidates that are under clinical investigation. None of such product candidates have been approved for marketing by the FDA or the EMA, and such product candidates are currently limited to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.






# Investment Highlights (NASDAQ: VYNE)

## Advancing novel BET inhibitor platform to improve the lives of patients suffering from immuno-inflammatory conditions

 <b>Innovative Target &amp; Approach</b>	<ul style="list-style-type: none"><li>• <b>BET inhibition represents a novel target for the treatment of autoimmune diseases: Addressing the complex signaling of immuno-inflammatory diseases by disrupting inflammatory gene transcription in T cells</b></li><li>• <b>Potential across broad range of immune-mediated diseases representing multi-billion-dollar opportunities</b></li></ul>
 <b>Clinical Stage Pipeline</b>	<ul style="list-style-type: none"><li>• <b>VYN201: Phase 1b PoC data in vitiligo suggest VYN201 has the potential to be category leader</b></li><li>• <b>VYN202: Supported by robust preclinical data across multiple diverse models of autoimmune disease, Phase 1a SAD/MAD expected to be initiated in Q2 2024</b></li></ul>
 <b>Potential for Multiple Clinical Catalysts</b>	<ul style="list-style-type: none"><li>• <b>VYN201: Phase 2b trial expected to be initiated in Q2 2024, with top-line results anticipated in mid-2025</b></li><li>• <b>VYN202: Phase 1a SAD/MAD read-out anticipated 2H 2024</b><ul style="list-style-type: none"><li>• <b>(2) Phase 1b PoC studies in plaque psoriasis and rheumatoid arthritis planned, with top-line results anticipated in 2H 2025</b></li></ul></li></ul>
 <b>Experienced Team &amp; Strong Balance Sheet</b>	<ul style="list-style-type: none"><li>• <b>Seasoned leadership team with demonstrated track record of progressing programs through regulatory approval</b></li><li>• <b>Cash: \$86.0M<sup>1</sup>; No debt</b> <b>Q4 2023 financing with syndicate of leading healthcare investors expected to provides cash runway through the end of 2025</b></li></ul>



# Building a Leading Early-Stage Pipeline to Address Unmet Needs in I&I Conditions

Program	Indication(s)	Route of Administration	Current Stage				Status / Next Anticipated Milestones	Rights
			Preclinical	IND-Enabling	Phase 1	Phase 2		
InhiBET™ Platform - Library of NCE BET Inhibitors for Any Indication Worldwide								
VYN201 Soft pan-BD BET inhibitor	Nonsegmental Vitiligo	Topical					<ul style="list-style-type: none"><li>• Phase 1 completed</li><li>• Q2 2024: Initiate P2b</li><li>• Mid-2025: TLR P2b</li></ul>	Worldwide
VYN202 BD2-selective BET inhibitor	Moderate-to-Severe Plaque Psoriasis	Oral					<ul style="list-style-type: none"><li>• Q2 2024: Initiate P1a SAD/MAD</li><li>• 2H 2024: TLR P1a SAD/MAD</li></ul>	Worldwide
	Moderate-to-Severe Rheumatoid Arthritis							
Ongoing evaluation for other autoimmune and fibro-inflammatory diseases								

# **InhiBET™ BET Inhibitor Platform**

**Bromodomain & Extra-Terminal Domain (BET) Inhibition for Immunology and Inflammatory Diseases**



**ROOTED IN  
INNOVATION**

# VYNE's Drug Design Strategy

Optimize benefit/risk profile of BET inhibitors to target autoimmune diseases

## VYN201

### Pan-BD BET Inhibitor

**Maximize local effect & minimize systemic exposure**


- Tissue targeted administration routes & formulations
- Soft drug / drug delivery strategies to reduce impact of BD1 inhibition on steady-state gene regulation

## VYN202

### BD2-Selective BET Inhibitor

**Improve efficacy and tolerability through BD2-selectivity**

- Class-leading BD2 vs. BD1 selectivity for systemic administration
- BD2 activity more relevant to inflammatory gene expression
- Minimize BD1 inhibition to protect against steady-state gene disruption



# VYN201: Vitiligo





# Vitiligo Represents a Large and Growing Market Opportunity



## Addressable Market : a Significant Unmet Need

1.9M

- **Market penetration:** Opzelura is the only product approved for treatment of vitiligo
- **Patient activation represents large long-term growth opportunity:**
  - Significant # of patients do not currently seek treatment due to lack of approved and effective treatment options
- **Annual net sales of ~\$10K / patient<sup>1</sup>**

<0.2M

U.S. Diagnosed Vitiligo Patients

Patients Currently Seeking Treatment

**Opzelura<sup>®</sup>**  
(ruxolitinib) cream 1.5%

\$ in millions

Est. 0.3M to 0.45M patients seeking treatment

LTM vitiligo net sales  
~\$150M within  
7 quarters of launch<sup>2</sup>

\$150

\$550

\$553

\$725

Q1 '24 LTM  
Vitiligo Net  
Sales

Cowen

Citi

Piper

Analyst 2030 Vitiligo U.S. Net Sales Estimates

Only one drug approved, treatment is dominated by non-specific therapies including topical steroids and phototherapy

Source: Gandhi et al. JAMA Dermatol. 2022;158(1):43-50; Kruger. 2012;51(10):1206-1212; Rangu. J Clin Dermatol Ther. 2021;7:070; Pandya. AAD 2023 Presentation; Incyte Corporate Pres. Aug. 2023; TD Cowen research dated Sept. 2023; Piper research dated Jan. 2023; Citi research dated July 2023


1. Opzelura estimated pricing: \$2k per 60g tube\*10 tubes per patient per year less GTN discount of 50% per Incyte mgmt.; 2. Estimated: Q1'24 LTM net sales \$367M with vitiligo representing ~40% of TRx per Incyte mgmt.



# BET Inhibition – A Differentiated Treatment Strategy for Non-Segmental Vitiligo

## BET Inhibition (VYN201)

- BET proteins recognize (“read”) acetylated lysine on the termini of histones that protrude from chromatin.
- **BET inhibition prevents transcriptional processing, leading to signal transduction termination.**




## JAK-STAT pathway Opzelura® (ruxolitinib)

- JAK activation phosphorylates receptors that form docking sites for STAT
- **JAK inhibition prevents STAT signal transduction into the nucleus.**

# Pathogenesis of Vitiligo is Primarily Linked to CD8+ T-Cell Proliferation and Hyperactivity


VYN201 has demonstrated marked inhibition of CD8+ t-cell expansion and activity at levels favorable to ruxolitinib

CD8+ T-cell Proliferation




VYN201 is superior to ruxolitinib in inhibiting CD8+ t-cell proliferation

CD8+ T-cell Activation Marker IFN $\gamma$



VYN201 IC50 for IFN $\gamma$  release superior to ruxolitinib

CD8+ T-cell Viability



VYN201 does not impart a cytotoxic effect on CD8+ t-cells at levels similar to ruxolitinib

# VYN201: Phase 1 Proof-of-Concept



# VYN201: Phase 1b Study in Active Vitiligo Patients

## Study Design

**Treatment on the face and target lesion on trunk of active vitiligo patients for up to 16 weeks of QD treatment**

- **N = up to 30: 3 cohorts, evaluating 0.5%, 1.0% and 2.0% strengths**
- Safety assessments include TEAEs, pharmacokinetics and local skin tolerance
- Exploratory efficacy assessments include F-VASI, biomarkers and photography

### **Key inclusion/exclusion criteria:**

- Subjects with a clinical diagnosis of active non-segmental vitiligo. An active vitiligo lesion is defined as evidence of hypochromic areas / borders and/or confetti-like depigmentation and/or peri-lesional inflammation and/or Koebner phenomenon.
- Facial-Vitiligo Area and Severity Index Score (F-VASI) of  $\geq 0.5$ .
- Two contralateral active vitiligo target lesions on non-facial anatomical areas. Non-facial target lesion areas should not include hands, wrists, feet, or elbows.
- The presence of leukotrichia should not exceed 50% of the full face or 50% of each non-facial target lesion.

## Primary objectives of Phase 1b:



1. **Assess safety, tolerability and pharmacokinetics**
2. **Evaluate VYN201's ability to arrest the progression of depigmentation in active vitiligo patients**
3. **Identify early evidence of repigmentation**
4. **Inform dose level / dose regimen of Phase 2b dose-ranging study**



# Vitiligo Disease Activity within PoC Study Designs



## Patient Population and Asset Development Status

	Disease Activity	Status
<b>VYN201 P1b</b> (VYNE)	<ul style="list-style-type: none"><li>• <b>Active Only</b></li></ul>	<ul style="list-style-type: none"><li>• PoC achieved</li><li>• Phase 1b completed</li></ul>
<b>Litfulo® (ritlecitinib) P2b<sup>1</sup></b> JAK3/TEC kinase inhibitor (Pfizer)	<ul style="list-style-type: none"><li>• <b>Active Only</b></li></ul>	<ul style="list-style-type: none"><li>• Pfizer currently enrolling P3 studies evaluating 50 mg QD dose in active &amp; stable disease</li></ul>
<b>Opzelura® (ruxolitinib) P2b<sup>3</sup></b> JAK1/JAK2 inhibitor (Incyte)	<ul style="list-style-type: none"><li>• <b>Active &amp; Stable</b></li></ul>	<ul style="list-style-type: none"><li>• 1.5% BID dose approved in the U.S. (July 2022) and EU (April 2023)</li></ul>
<b>Povorcitinib P2b<sup>2</sup></b> JAK1 inhibitor (Incyte)	<ul style="list-style-type: none"><li>• <b>Active &amp; Stable</b></li></ul>	<ul style="list-style-type: none"><li>• Incyte currently enrolling P3 studies</li></ul>
<b>Rinvoq® (upadacitinib) P2b<sup>4</sup></b> JAK1/JAK2 inhibitor (AbbVie)	<ul style="list-style-type: none"><li>• <b>Active &amp; Stable</b></li></ul>	<ul style="list-style-type: none"><li>• Phase 2b completed</li></ul>

VYNE expects to enroll patients with active and stable disease in P2b study



Patients with Active Disease Will Continue to Depigment in Areas that Show High Activity without Therapy<sup>5</sup>

**Fig 1:**  
Vitiligo of the hand with confetti-like depigmentation





**Fig 2:**  
16 weeks later  
Showing extension of depigmentation and new areas of confetti-like depigmentation



Physicians expect patients with active disease to be more difficult to treat


# Promising Onset of Action and F-VASI Response

## VYN201 Phase 1b: QD Treatment in 100% active disease study population



# Demonstrated Competitive Efficacy at 16 Weeks vs. JAK Class at 24 Weeks

## VYN201 Phase 1b: QD Treatment in 100% active disease study population



Note: Data is not based on Head-to-Head comparisons; Source: Clinicaltrials.gov; Study Publications: 1. NCT03715829 (LS mean %CFB for 50 mg QD); 2. NCT04818346 (LS mean %CFB for 45 mg QD); 3. NCT03099304 (LS mean %CFB for 1.5% BID); 4. NCT04927975 (LS mean %CFB for 11 mg QD);


# Preclinical & Clinical Data Highlight Potential for Differentiated Product Profile

Characteristic	VYN201		Opzelura (Ruxolitinib) Cream 1.5%	Litfulo (Ritlecitinib) 50mg <sup>1</sup>	Povorcitinib 45mg <sup>2</sup>
	1%	2%			
Novel MOA / JAK Class Alternative	✓		✗	✗	✗
Targeted Dosing Posology	QD		BID	QD	QD
Rapid Onset of Action	✓		Moderate	✗	Moderate
Efficacy, % CFB F-VASI, <u>Week 16</u>	<u>100% active disease study</u>		<u>Active &amp; stable disease study</u> P2b: -37.8 ( <u>Week 24</u> ) <sup>3</sup>	<u>100% active disease study</u> -1.8 ( <u>Week 8</u> ) -18.5 ( <u>Week 24</u> )	<u>Active &amp; stable disease study</u> -36.4 ( <u>Week 24</u> )
	-30.2	-39.0			
Efficacy, % F-VASI50, <u>Week 12</u> <sup>5</sup>	20.0	33.3	P2b: 21.2 <sup>3</sup> P3: 29.2 <sup>4</sup>	0.0 ( <u>Week 8</u> ) 15.4 ( <u>Week 24</u> )	25.0
Potential to Upregulate WNT Pathway <sup>6</sup>	✓		✗	✗	✗
Safety Precaution	-		✗ “Black Box”	✗ “Black Box”	✗ Expect “Black Box”
Systemic Exposure	Low (Cmax <1 nM)		Cmax/AUC: 449nM / 3215nM	-	-

Data is not based on Head-to-Head comparisons  
Source: Clinicaltrials.gov; Data on file 1.NCT03715829 2. NCT04818346; 3. NCT03099304; 4. Pooled analysis TRuE-V1 and TRuEV2 Incyte Corporate Presentation dated July 19, 2022;  
5. Week 16 data for JAK class not available; 6. Based on preclinical data



**Phase 1b Select Images**  
Subject with near-complete depigmentation (High FVASI)



Baseline




Week 16

(0.5% cohort, Fitzpatrick skin type: 5)

**Phase 1b Select Images**  
Subject with significant repigmentation response



Baseline



Week 16


(2.0% cohort, Fitzpatrick skin type: 2)



# Phase 1b Select Images

Subject examples with marked active disease

Confetti-like depigmentation presentation



Baseline

Week 16

(1.0% cohort, Fitzpatrick skin type: 6)

Inflamed vitiligo presentation



Baseline



Week 16

(2.0% cohort, Fitzpatrick skin type: 5)

# Key Takeaways from VYN201 Phase 1b Results



- Significant clinical response shown with rapid onset of action
- Clear evidence of dose response



- Efficacy data suggest potential to be category leader
- Favorable efficacy results and onset of action compared with the JAK competitive landscape in a more difficult to treat patient population (active disease vs. stable disease)



- Demonstrated favorable safety and tolerability profile to date
- Low systemic exposure levels support “soft” drug design




- Believed to be first clinical demonstration of BET inhibitor’s effect in autoimmune disease<sup>1</sup>



# VYN201 Phase 2b in Non-Segmental Vitiligo (NSV)

## Top-line results from 24-week vehicle-controlled treatment period expected mid-2025



# VYN202: BD2 selective BET inhibitor



# VYNE's Drug Design Strategy

Optimize benefit/risk profile of BET inhibitors to target autoimmune diseases

## VYN201

### Pan-BD BET Inhibitor

**Maximize local effect & minimize systemic exposure**


- Tissue targeted administration routes & formulations
- Soft drug / drug delivery strategies to reduce impact of BD1 inhibition on steady-state gene regulation

## VYN202

### BD2-Selective BET Inhibitor


**Improve efficacy and tolerability through BD2-selectivity**

- Class-leading BD2 vs. BD1 selectivity for systemic administration
- BD2 activity more relevant to inflammatory gene expression
- Minimize BD1 inhibition to protect against steady-state gene disruption



# Maximizing On-target Potency vs. BD2 and Minimizing Affinity to BD1 May Be The Key to Optimizing the Benefit/Risk Profile of BET Inhibitors for Autoimmune Diseases

VYN202 is believed to be the most potent and BD2-selective BET Inhibitor in development<sup>1</sup> which is designed to improve efficacy and tolerability



**BD2** activity is associated with inflammatory gene induction that drives inflammatory responses in autoimmune disease

**BD1** regulates “housekeeping” gene activity




Compound ID	Potency vs. BD2* (nM)	Selectivity** (BD1/BD2)
VYN202 (VYNE)	<	>>>>
NUV-868 (Nuvation) <sup>2</sup>	2	1,460x (FRET)
ABBV-744 (AbbVie) <sup>3</sup>	28	753x (FRET)
GSK620 (GSK) <sup>4</sup>	79	220x
Pelabresib (Constellation) <sup>2</sup>	17	5x (FRET)
ABBV-075 <sup>3</sup>	13	2.6x
MK-8628/OTX-015 <sup>5</sup>	26	1.5x
BI-894999 <sup>6</sup>	41	0.1x

\*Lower number denotes higher potency  
\*\*Higher number denotes higher selectivity. Data based on nanoBRET assay unless otherwise indicated.

1. Based on readily available public information such as clintrials.gov, academic publications and corporate websites/presentations. 2. Nuvation corporate presentation (January 2024); 3. Faivre et al 2020; 4. Delmont et al 2020; 5. Wang et al 2017 6. Kraut et al 2018; Data on file




# Strategies to Control Dysregulated T<sub>H</sub>17 Immune Cell Activity



## Existing strategies target:



- Extracellular cytokines
- Cytokine receptor inhibition or
- Inhibition of trans-cellular inflammatory signal propagation

# BET Inhibitors Disrupt Inflammatory Gene Transcription in T Cells to Directly Address the Complex Signaling of Immuno- & Fibro-inflammatory Diseases



# Demonstrated Potency Against Th17 Cytokines

## VYN202 Potency vs. IL-17A compares favorably to Secukinumab and DC-806



Therapeutic Agent	IC50 <sub>IL17A</sub> (nM)
VYN202 (VYNE)	0.27
Secukinumab (Cosentyx - NVS):	0.37
DC-806 (DICE/LLY)	5.7

# Minimal Inhibition on Key Innate Immune Chemokine Demonstrates Selectivity of Cytokine Expression (IL-17A and IL-22 vs. CXCL10)

Cytokine	VYN202 IC <sub>50</sub> (nM)	Selectivity vs. CXCL10
IL-17A	0.27	>13,000
IL-22	0.21	>17,000
CXCL10	3637	-

- VYN202 significantly more potent against Th17 Cytokines vs. CXCL10
- CXCL10 interacts with CXCR3 to attract Th1 cells, eosinophils, monocytes, and NK cells to sites of inflammation and is known to be an important part of host defense mechanism

# Preclinical Efficacy Models







# VYN202: Psoriasis Model





# VYN202: Comparable Onset of Action and Efficacy to Deucravacitinib<sup>1</sup> at Equivalent Dosing in Preclinical *in vivo* Model of Psoriasis

Dorsal depilated BALB-C mice were dosed for 14 days with topical imiquimod cream (Day 1-7: induction phase, Day 8-14: treatment phase). N=8 animals were assigned to each treatment group and received 3 mg/kg of allocated treatment intraperitoneally dosed once-daily on Day 8-14.



<sup>1</sup>Sotyktu® (deucravacitinib) was approved in the U.S. in September 2022.  
PASI-90 = 90% improvement from baseline in PASI score

# VYN202 Reduced Key Cytokines Associated with Pathogenesis of Psoriasis in Preclinical *in vivo* Model



- >93% lower expression of IL-17 at all VYN202 doses compared to placebo

- Marked reduction of other disease related Th17 and Th1 cytokines

# VYN202: Marked Improvement in Clinical Presentation of Disease

Comparable to deucravacitinib in resolving induced dermal inflammation at an identical dose after 7 days of treatment

**Day 8**  
Before treatment



**Day 15**  
After 7 days of treatment





# VYN202: Rheumatoid Arthritis Model





# VYN202: Collagen-Induced Arthritis Model in the Rat – Arthritis Score

- VYN202 demonstrated highly potent anti-inflammatory activity
- VYN202 statistically superior to GSK620 (BD2-selective BET inhibitor) at all dose levels




- VYN202 10mg/kg PO QD treatment resulted in a 71% lower clinical score and 79% lower paw volume compared to CIA+Placebo control at Day 21
- All VYN202 treatment groups were statistically significantly superior to both CIA+Placebo and GSK620 10mg/kg PO QD controls


# VYN202: Collagen-Induced Arthritis Rat Model – Histology Score & Biomarkers

- Treatment with VYN202 at 10mg/kg PO QD results in near normal joint histopathology
- VYN202 demonstrated near complete inhibition of IgG1\* expression at all doses

Histology Scores - Day 21



IgG1 (units/ml) - Day 21





- CIA+VYN202 treatment resulted in a dose-dependent reduction in severity of arthritic histopathology & was statistically superior to CIA+Placebo and CIA+GSK620 at all doses
- VYN202 10mg/kg PO QD reduced the expression of IgG1 by >98% vs. CIA+Placebo control & was statistically equivalent to Placebo control

\*Immunoglobulin G1

Note: Histology - Mixed cell inflammation; tissue granulation; increased bone, periosteum; increased eroded surface bone and cartilaginous erosion/ulceration were assessed on a 4-point severity scale: minimal (1), mild (2), moderate (3) and marked(4). Composite histopathology score was calculated by summing each assessment by severity and incidence. Maximum score: 160 (5 x 4 x N=8/group).

# VYN202 Results Show Strong Correlation with VYN201 Results

Reinforcing BET potential and role of BD2 inhibition in treatment of autoimmune diseases



# VYN202 Clinical Development Plan

- 1. Moderate-to-Severe Psoriasis**
- 2. Moderate-to-Severe Active Rheumatoid Arthritis**






# Clinical Development Strategy

Initial PoC studies in psoriasis and rheumatoid arthritis serve as potential gateway to other large, strategically attractive markets


Global Sales<sup>1</sup>, USD Bn

Prevalence<sup>2</sup>, %



39 Source: 1. Global Data; ABBV 2020 Long-term Strategy Corporate Presentation; Data on file 2. Alotaibi HM Clin Cosmet Investig Dermatol. 2023; MacGearailt C., Fitzgerald, G. EMJ Rheumatol. 2021; Ogdie A, Weiss P. Rheum Dis Clin North Am. 2015; Armstrong, et al. JAMA Dermatol. 2021; RA Xu Y, Wu Q. J Clin Med. 2021

# VYN202 Planned Study Designs



PoC data in PsO and RA provide significant optionality and unlock potential opportunities in other indications such as PsA, AS and HS in P2 and beyond

# VYN202 Program Summary



- **Novel, highly differentiated MOA - acting at the point of gene transcription in T Cells to directly address the complex signaling of immuno- & fibro-inflammatory diseases**
- **BET Inhibition's impact on multiple inflammatory pathways unlocks potential across broad range of immune-mediated diseases**



- **Historical pan-BD BET safety concerns addressed via potential class-leading selectivity and potency vs. BD2 binding domain**




- **Strong preclinical data across multiple diverse models of autoimmune disease demonstrating significant down regulation of key pro-inflammatory & disease-related biomarkers with corresponding improvements in disease severity**



- **VYN202 preclinical efficacy results show strong correlation with VYN201 results reinforcing drug design thesis and BET inhibition potential in psoriasis, rheumatoid arthritis, and other TH17 driven diseases**

# Multiple Paths to Potential Value Creation Across BET Inhibitor Programs





NASDAQ: VYNE



# Appendix




# VYN201: Preclinical Data




# VYN201: Human Tissue Model of Vitiligo

## Demonstrated reduction in melanocyte loss and lowering of key inflammatory biomarkers


VYN201 1% reduced the secretion of MMP9 relative to stimulated vehicle, and numerically superior to ruxolitinib 1.5%



VYN201 affects a dose-dependent reduction in solubilized E-cadherin




VYN201 substantially prevents the loss of melanin pigment in the basal layers of skin in a dose dependent manner




# VYN201: Human Tissue Model of Vitiligo

VYN201 prevents melanocyte detachment, down regulates the expression of key cytokines and upregulates WNT pathway




Clear evidence of melanocyte adhesion disruption, melanocyte detachment and migration through the skin



VYN201 1% prevents detachment and subsequent loss of melanocytes from the basal layer implying that E-cadherin adhesion is still functional

Keratinocytes (blue), melanocytes (green)




Significant downregulation of cytokines IL6, IL1A and IL1B and TNF $\alpha$  and upregulation of the WNT pathway (Wnt16)

# VYN201: Phase 1 Proof-of-Concept










# Baseline Demographic and Clinical Characteristics

	0.5% Cohort (N=10)		1% Cohort (N=10)		2% Cohort (N=9)		Total (N=29)	
Age - year mean	49.2		53.2		57.0		52.9	
Age group - no. / %	0	0%	0	0%	0	0%	0	0%
12-17	0	0%	0	0%	0	0%	0	0%
18-64	9	90%	8	80%	8	89%	25	86%
>=65	1	10%	2	20%	1	11%	4	14%
Female sex - no. / %	6	60%	7	70%	7	78%	20	69%
Race or ethnic group								
Hispanic or Latino	0	0%	2	20%	7	78%	9	31%
Not Hispanic or Latino	10	100%	8	80%	2	22%	20	69%
Fitzpatrick Skin type - no. / %								
I	0	0%	0	0%	0	0%	0	0%
II	5	50%	4	40%	1	11%	10	34%
III	1	10%	3	30%	3	33%	7	24%
IV	3	30%	2	20%	4	44%	9	31%
V	0	0%	0	0%	1	11%	1	3%
VI	1	10%	1	10%	0	0%	2	7%
F-VASI mean / (min-max)	1.34	(0.54-3.21)	1.14	(0.51-3.36)	0.83	(0.51-1.92)	1.11	(0.51-3.36)
Disease stability - no. / %								
Active / Progressive	10	100%	10	100%	9	100%	29	100%
Stable	0	0%	0	0%	0	0%	0	0%




# Demonstrated Favorable Safety & Tolerability Profile

 Adverse Events	
	No serious adverse events reported
	No treatment related discontinuations
	All treatment emergent adverse events classified as mild (>70%) or moderate; no severe AEs
	No dose/exposure-dependent increases in AEs
	No significant alterations in clinical safety lab parameters, with no impact on platelet counts


 Local Skin Tolerability	
Assessment	Mean Score Range 0 (None) to 3 (Severe)
Burning/Stinging	0.26
Scaling	0.15
Dryness	0.22
Pruritus	0.14
Erythema	0.29
Hyperpigmentation	0.10

# VYN201 Phase 1b: Low Systemic Exposure in Vitiligo Subjects Correlates with No Impact on Platelet Counts

Available data for treatment up to 16 weeks supports “soft” drug approach for topical pan-BD BET inhibitor



- VYN201 concentrations markedly below free EC50BD1 BRD4 at all dose levels for available data for treatment up to 16 weeks
- Assay LLOQ is 720-fold lower than the free EC50<sub>BD1 BRD4</sub> for VYN201



- All platelet counts remain within normal range
- No trends suggestive of reducing counts by treatment duration
- Similar lack of effect on neutrophils, eosinophils, lymphocytes, basophils and monocytes (data not shown)